Table 3

Sight loss attributable to ‘wet’ age-related macular degeneration: estimated number of affected persons in the UK in relation to three assumed levels of anti-VEGF treatment coverage for neovascular AMD

Sight loss from NV-AMDYear: 201020152020
Assumed treatment coverage: 50%149 326173 994193 804
75%145 697170 272189 890
90%143 519167 992187 523
  • AMD, age-related macular degeneration; NV-AMD, neovascular (wet) AMD; Sight loss, corrected visual acuity <6/12 in the better seeing eye; VEGF, vascular endothelial growth factor.